Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) has signed a strategic partnership with PharmaJet for the supply of the Stratis intramuscular (IM) needle-free injection system.
The system will be used for the delivery of Scancell’s SCIB1/iSCIB1+ DNA cancer vaccine for patients with advanced or metastatic melanoma.
The Stratis system has shown effective uptake of the SCIB1/iSCIB1+ DNA vaccine in clinical studies.
To date, 60 patients across 15 clinical sites have received 171 doses of the vaccine via Stratis, which is also US FDA cleared, CE Marked, and WHO prequalified.
The needle-free delivery system is designed to offer patients a convenient and effective treatment option.
Prof Lindy Durrant, chief executive of Scancell, said: "Securing long term supply for the PharmaJet Stratis Intramuscular needle-free injection system is an important step in allowing the clinical and commercial development of SCIB1/iSCIB1+.
“We are pleased that PharmaJet's delivery system works effectively with our SCIB1/iSCIB1+ therapeutic cancer vaccines and offers a well-received immunisation for patients."
Nathalie Landry, chief scientific officer at PharmaJet, added: "We are excited to partner with Scancell to develop and commercialise their SCIB1/iSCIB1+ DNA vaccine for advanced melanoma.
“This partnership aligns with PharmaJet's strategy to enable improved delivery of nucleic acid-based vaccines and therapies for oncology."